Redeye updates on Vitrolife after a site visit and a change of lead analyst. The company continues exhibiting key hallmarks of quality, yet its shares are trading near a five-year low. While strategic initiatives are in place to address the muted growth trajectory observed over the past few years, we argue sustained acceleration will be required for the stock to regain momentum. We believe the market is likely to wait for tangible evidence of improved growth trajectory before re-rating the shares.
LÄS MER
